Did Myriad Genetics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - MYGN
Portfolio Pulse from
Levi & Korsinsky has launched an investigation into Myriad Genetics, Inc. for potential violations of federal securities laws. This follows UnitedHealth Group's decision to stop covering Myriad's GeneSight test starting January 1, 2025.
November 13, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Myriad Genetics is under investigation for potential securities law violations after UnitedHealth announced it would stop covering GeneSight, a key product, from January 2025.
The investigation by Levi & Korsinsky into Myriad Genetics for potential securities law violations is significant, especially following UnitedHealth's decision to cease coverage of GeneSight. This could negatively impact Myriad's revenue and investor confidence, likely leading to a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100